Anakinra is a regimen that large studies have indicated does not show great efficacy in pustular psoriasis subtype [50] and it is used particularly in patients with revealed IL36RN pathogenic gene variants [51], as Anakinra blocks the action of IL-1 by binding to its receptor, which in healthy individuals is normally blocked by IL36 antagonist. Here, IL1B is linked to pustular psoriasis.